Miller M L, Daniels M D, Wang T, Wang Y, Xu J, Yin D, Chong A S, Alegre M-L
Section of Rheumatology, Department of Medicine, The University of Chicago, Chicago, IL.
Section of Transplantation, Department of Surgery, The University of Chicago, Chicago, IL.
Am J Transplant. 2016 Oct;16(10):2854-2864. doi: 10.1111/ajt.13814. Epub 2016 May 5.
Solid organ transplantation tolerance can be achieved following select transient immunosuppressive regimens that result in long-lasting restraint of alloimmunity without affecting responses to other antigens. Transplantation tolerance has been observed in animal models following costimulation or coreceptor blockade therapies, and in a subset of patients through induction protocols that include donor bone marrow transplantation, or following withdrawal of immunosuppression. Previous data from our lab and others have shown that proinflammatory interventions that successfully prevent the induction of transplantation tolerance in mice often fail to break tolerance once it has been stably established. This suggests that established tolerance acquires resilience to proinflammatory insults, and prompted us to investigate the mechanisms that maintain a stable state of robust tolerance. Our results demonstrate that only a triple intervention of depleting CD25 regulatory T cells (Tregs), blocking programmed death ligand-1 (PD-L1) signals, and transferring low numbers of alloreactive T cells was sufficient to break established tolerance. We infer from these observations that Tregs and PD-1/PD-L1 signals cooperate to preserve a low alloreactive T cell frequency to maintain tolerance. Thus, therapeutic protocols designed to induce multiple parallel mechanisms of peripheral tolerance may be necessary to achieve robust transplantation tolerance capable of maintaining one allograft for life in the clinic.
通过某些短暂的免疫抑制方案可实现实体器官移植耐受,这些方案能长期抑制同种异体免疫,同时不影响对其他抗原的反应。在共刺激或共受体阻断疗法后的动物模型中,以及在一部分通过包括供体骨髓移植的诱导方案或免疫抑制撤减后的患者中,均观察到了移植耐受。我们实验室及其他机构之前的数据表明,在小鼠中成功预防移植耐受诱导的促炎干预措施,一旦耐受稳定建立,往往无法打破它。这表明已建立的耐受获得了对促炎损伤的抵抗力,并促使我们研究维持强大耐受稳定状态的机制。我们的结果表明,只有同时进行清除CD25调节性T细胞(Tregs)、阻断程序性死亡配体-1(PD-L1)信号以及转移少量同种异体反应性T细胞这三种干预,才足以打破已建立的耐受。我们从这些观察结果推断,Tregs和PD-1/PD-L1信号协同作用,以维持低水平的同种异体反应性T细胞频率来维持耐受。因此,可能需要设计旨在诱导多种外周耐受平行机制的治疗方案,以在临床上实现能够终身维持一个同种异体移植物的强大移植耐受。